

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Mark E. Fraley, et al.	Art Unit:
Attorney Docket No.	21405YP	To be determined
PCT Appl. No.:	PCT/US04/018065	Filed: 8 June 2004
Filing Date:	December 7, 2005	
For:	PRODRUGS OF MITOTIC KINESIN INHIBITORS	

Mail Stop: PCT
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

LETTER

Sir:

In compliance with 37 C.F.R. 1.821(f) of the Rules of Practice In Patent Cases: Application Disclosures Containing Nucleotide And/Or Amino Acid Sequences, the signature page and following statement are being submitted herewith.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

The enclosed diskette contains the Sequence Listing for case number 21405YP.

Respectfully submitted,

By:

David A. Muthard
Registration No. 35,297
Attorney for Applicants

Merck & Co., Inc.
P.O. Box 2000 – RY 60-30
Rahway, New Jersey 07065-0907
Telephone No. (732) 594-3903

Date: December 7, 2005

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT Dec. 7, 2005
EXPRESS MAIL NO. EV421343126US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VIRGINIA 22313-1450.
MAILED BY Doni Schepker
DATE 12-7-05